[Skip to Content]
[Skip to Content Landing]
February 1988

Poliomyelitis Prevention: Enhanced-Potency Inactivated Poliomyelitis Vaccine—Supplementary Statement

Am J Dis Child. 1988;142(2):139-140. doi:10.1001/archpedi.1988.02150020037022

Dec 11, 1987 (Vol. 258, No.22).—THE SUPPLEMENTARY statement provides information on and recommendations for the use of inactivated poliovirus vaccine (IPV) of enhanced potency.* The Immunization Practices Advisory Committee (ACIP) believes that, in the United States, polio immunization should rely primarily on oral poliovirus vaccine (OPV), with selected use of enhanced-potency IPV as specified in this document. However, this subject should be reviewed on a continuing basis, and an extensive review of polio vaccines and potential vaccine policies will take place during 1988. General recommendations on poliomyelitis prevention, including the use of and schedules for OPV, are found in the current ACIP recommendations.1

Introduction  Conventional IPV. IPV was introduced in the United States in 1955 and was used widely until OPV became available during the period 1961-1964. Thereafter, the use of IPV rapidly declined to a level of less than 1% of all polio vaccine distributed annually in the

First Page Preview View Large
First page PDF preview
First page PDF preview